{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:34:06Z","timestamp":1780922046557,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"DOI":"10.7759\/cureus.55242","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T15:24:16Z","timestamp":1709220256000},"source":"Crossref","is-referenced-by-count":1,"title":["Delayed Postoperative Intracerebral Hemorrhage Associated With Oral Multikinase Inhibitor Therapy for Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Vishal C","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Krishnakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Poklepovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Broaddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai H","year":"2019","unstructured":"Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019, 81:101912. 10.1016\/j.ctrv.2019.101912","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020455","article-title":"Recent advancements of nanomedicine towards antiangiogenic therapy in cancer","volume":"21","author":"Mukherjee A","year":"2020","unstructured":"Mukherjee A, Madamsetty VS, Paul MK, Mukherjee S. Recent advancements of nanomedicine towards antiangiogenic therapy in cancer. Int J Mol Sci. 2020, 21:455. 10.3390\/ijms21020455","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228689","article-title":"The angiopoietin-2 and TIE pathway as a therapeutic target for enhancing antiangiogenic therapy and immunotherapy in patients with advanced cancer","volume":"21","author":"Leong A","year":"2020","unstructured":"Leong A, Kim M. The angiopoietin-2 and TIE pathway as a therapeutic target for enhancing antiangiogenic therapy and immunotherapy in patients with advanced cancer. Int J Mol Sci. 2020, 21:8689. 10.3390\/ijms21228689","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S162967","article-title":"Molecular characterization and biomarker identification in colorectal cancer: toward realization of the precision medicine dream","volume":"10","author":"Goel G","year":"2018","unstructured":"Goel G. Molecular characterization and biomarker identification in colorectal cancer: toward realization of the precision medicine dream. Cancer Manag Res. 2018, 10:5895-908. 10.2147\/CMAR.S162967","journal-title":"Cancer Manag Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich TJ","year":"2018","unstructured":"Ettrich TJ, Seufferlein T. Regorafenib. Recent Results Cancer Res. 2018, 211:45-56. 10.1007\/978-3-319-91442-8_3","journal-title":"Recent Results Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S88825","article-title":"Evolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a \"me too\" drug?","volume":"10","author":"Goel G","year":"2018","unstructured":"Goel G. Evolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a \"me too\" drug?. Cancer Manag Res. 2018, 10:425-37. 10.2147\/CMAR.S88825","journal-title":"Cancer Manag Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm SM","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, et al.. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011, 129:245-55. 10.1002\/ijc.25864","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0938-y","article-title":"Regorafenib: a review in metastatic colorectal cancer","volume":"78","author":"Dhillon S","year":"2018","unstructured":"Dhillon S. Regorafenib: a review in metastatic colorectal cancer. Drugs. 2018, 78:1133-44. 10.1007\/s40265-018-0938-y","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.09.015","article-title":"Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study","volume":"123","author":"Ducreux M","year":"2019","unstructured":"Ducreux M, Petersen LN, \u00d6hler L, et al.. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Eur J Cancer. 2019, 123:146-54. 10.1016\/j.ejca.2019.09.015","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.847110","article-title":"Surgical management of brain metastasis: challenges and nuances","volume":"12","author":"Ene CI","year":"2022","unstructured":"Ene CI, Ferguson SD. Surgical management of brain metastasis: challenges and nuances. Front Oncol. 2022, 12:847110. 10.3389\/fonc.2022.847110","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-014-0333-x","article-title":"Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists","volume":"10","author":"Rey JB","year":"2015","unstructured":"Rey JB, Launay-Vacher V, Tournigand C. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. Target Oncol. 2015, 10:199-213. 10.1007\/s11523-014-0333-x","journal-title":"Target Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15580743","article-title":"Management of regorafenib-related toxicities: a review","volume":"8","author":"Krishnamoorthy SK","year":"2015","unstructured":"Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V, Saif MW. Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol. 2015, 8:285-97. 10.1177\/1756283X15580743","journal-title":"Therap Adv Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12109","article-title":"The coagulation system in host defense","volume":"2","author":"Antoniak S","year":"2018","unstructured":"Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018, 2:549-57. 10.1002\/rth2.12109","journal-title":"Res Pract Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67456-x","article-title":"Endoscopic hematoma removal of supratentorial intracerebral hemorrhage under local anesthesia reduces operative time compared to craniotomy","volume":"10","author":"Katsuki M","year":"2020","unstructured":"Katsuki M, Kakizawa Y, Nishikawa A, Yamamoto Y, Uchiyama T. Endoscopic hematoma removal of supratentorial intracerebral hemorrhage under local anesthesia reduces operative time compared to craniotomy. Sci Rep. 2020, 10:10389. 10.1038\/s41598-020-67456-x","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.06.006","article-title":"Endoscopy in temporal lobe glioma and metastasis resection: is there a role?","volume":"117","author":"Ma R","year":"2018","unstructured":"Ma R, Coulter CA, Livermore LJ, Voets NL, Al Awar O, Plaha P. Endoscopy in temporal lobe glioma and metastasis resection: is there a role?. World Neurosurg. 2018, 117:e238-51. 10.1016\/j.wneu.2018.06.006","journal-title":"World Neurosurg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006577","article-title":"Anti-VEGF therapies in the clinic","volume":"2","author":"Meadows KL","year":"2012","unstructured":"Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med. 2012, 2:a006577. 10.1101\/cshperspect.a006577","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma","volume":"20","author":"Brandes AA","year":"2015","unstructured":"Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015, 20:166-75. 10.1634\/theoncologist.2014-0330","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt051","article-title":"Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors","volume":"43","author":"Narita Y","year":"2013","unstructured":"Narita Y. Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin Oncol. 2013, 43:587-95. 10.1093\/jjco\/hyt051","journal-title":"Jpn J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2155-4","article-title":"Bevacizumab and central nervous system (CNS) hemorrhage","volume":"71","author":"Letarte N","year":"2013","unstructured":"Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013, 71:1561-5. 10.1007\/s00280-013-2155-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032312","article-title":"Cabozantinib, vandetanib, pralsetinib and selpercatinib as treatment for progressed medullary thyroid cancer with a main focus on hypertension as adverse effect","volume":"24","author":"H\u00f8jer Wang L","year":"2023","unstructured":"H\u00f8jer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, vandetanib, pralsetinib and selpercatinib as treatment for progressed medullary thyroid cancer with a main focus on hypertension as adverse effect. Int J Mol Sci. 2023, 24:2312. 10.3390\/ijms24032312","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1733","article-title":"Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO Trial","volume":"28","author":"Lee JM","year":"2022","unstructured":"Lee JM, Moore RG, Ghamande S, et al.. Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO Trial. Clin Cancer Res. 2022, 28:4186-93. 10.1158\/1078-0432.CCR-21-1733","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-022-02134-9","article-title":"Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis","volume":"11","author":"Yuan Y","year":"2022","unstructured":"Yuan Y, Liu X, Cai Y, Li W. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. Syst Rev. 2022, 11:264. 10.1186\/s13643-022-02134-9","journal-title":"Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13736","article-title":"Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: a preliminary study","volume":"25","author":"Kimura M","year":"2023","unstructured":"Kimura M, Go M, Yamada S, Asano H, Usami E, Yoshimura T. Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: a preliminary study. Oncol Lett. 2023, 25:150. 10.3892\/ol.2023.13736","journal-title":"Oncol Lett"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044096","article-title":"A novel preclinical in vitro 3D model of oral carcinogenesis for biomarker discovery and drug testing","volume":"24","author":"Chitturi Suryaprakash RT","year":"2023","unstructured":"Chitturi Suryaprakash RT, Shearston K, Farah CS, et al.. A novel preclinical in vitro 3D model of oral carcinogenesis for biomarker discovery and drug testing. Int J Mol Sci. 2023, 24:4096. 10.3390\/ijms24044096","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions","volume":"22","author":"Galli JA","year":"2017","unstructured":"Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017, 22:1171-8. 10.1111\/resp.13024","journal-title":"Respirology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2021.2241","article-title":"Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma","volume":"14","author":"Kamachi N","year":"2021","unstructured":"Kamachi N, Shimose S, Hirota K, et al.. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol. 2021, 14:79. 10.3892\/mco.2021.2241","journal-title":"Mol Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-016-0050-y","article-title":"Elevated prothrombin time\/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer","volume":"2","author":"Kitade H","year":"2016","unstructured":"Kitade H, Hiromasa-Yamasaki A, Hokkoku K, Mori M, Watanabe M, Nakai M, Yano S. Elevated prothrombin time\/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. J Pharm Health Care Sci. 2016, 2:15. 10.1186\/s40780-016-0050-y","journal-title":"J Pharm Health Care Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000328","article-title":"Antiangiogenic therapy in colorectal cancer","volume":"24","author":"Mody K","year":"2018","unstructured":"Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer. Cancer J. 2018, 24:165-70. 10.1097\/PPO.0000000000000328","journal-title":"Cancer J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020461","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Randrup Hansen C","year":"2017","unstructured":"Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017, 18:461. 10.3390\/ijms18020461","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.015","article-title":"Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients","volume":"71","author":"Tovoli F","year":"2019","unstructured":"Tovoli F, Ielasi L, Casadei-Gardini A, et al.. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019, 71:1175-83. 10.1016\/j.jhep.2019.08.015","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.08.005","article-title":"Temporal characteristics of adverse events of tivozanib and sorafenib in previously treated kidney cancer","volume":"20","author":"Zengin ZB","year":"2022","unstructured":"Zengin ZB, Pal SK, McDermott DF, et al.. Temporal characteristics of adverse events of tivozanib and sorafenib in previously treated kidney cancer. Clin Genitourin Cancer. 2022, 20:553-7. 10.1016\/j.clgc.2022.08.005","journal-title":"Clin Genitourin Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0069-5","article-title":"Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies","volume":"30","author":"Grande E","year":"2013","unstructured":"Grande E, Kreissl MC, Filetti S, et al.. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013, 30:945-66. 10.1007\/s12325-013-0069-5","journal-title":"Adv Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S393519","article-title":"Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022","volume":"17","author":"Schmidt-Ott U","year":"2023","unstructured":"Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z, Leal S, Morgan-Warren P, Zhang X, Johnson KT. Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022. Clin Ophthalmol. 2023, 17:385-90. 10.2147\/OPTH.S393519","journal-title":"Clin Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204520-delayed-postoperative-intracerebral-hemorrhage-associated-with-oral-multikinase-inhibitor-therapy-for-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T15:24:18Z","timestamp":1709220258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204520-delayed-postoperative-intracerebral-hemorrhage-associated-with-oral-multikinase-inhibitor-therapy-for-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.55242","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}